19 estudos demonstram imunidade cruzada e inata

19 estudos demonstram imunidade cruzada e inata

A mentira fétida do “não temos imunidade” foi isso mesmo, uma mentira de seres asquerosos que, em nome de sabe-se lá o quê, deitaram fora séculos de clínica e epidemiologia.

Todos os estudos sobre células T e B indicam a existência de elevadas percentagens de imunidade inata e cruzada. Todos. Muitos deles com imunidade acima de 90%

All studies testing memory B cells and T cells (CD4+ and CD8+) and nearly all studies testing antibodies show cross-reactivity to SARS-CoV-2 in subjects from wide geographical locations; some T cell studies showed >90% cross-reactivity

Memory B and T cells were also cross-reactive with SARS-CoV-1, indicating that this type of immunity can last for at least 17 years.




[2] Tso FY, Lidenge SJ, Pena PB et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis.102(2021)577–583
[3] Nguyen-Contant P, Embong K, Kanagaiah P et al. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. 10.1128/mBio.01991-20. https://doi.org/10.1128/mBio.01991-20
[4] Song G, He WT, Callaghan S et al. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. https://doi.org/10.1101/2020.09.22.308965
[5] Ng KW, Faulkner N, Cornish GH. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 11 Dec 2020: Vol. 370, Issue 6522, pp. 1339-1343 DOI: 10.1126/science.abe1107
[6] Braun J, Loyal L, Frentsch M et al. Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors. https://doi.org/10.1101/2020.04.17.20061440
[7] Mateus J, Grifoni A, Tarke A et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020; 370, 89–94
[8] Grifoni A, Weiskopf D, Ramirez SI et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181, 1489–1501
[9] Sekine T, Perez-Potti A, Rivera-Ballesteros O et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183, 158–168; https://doi.org/10.1016/j.cell.2020.08.017
[10] Nelde A, Bilich T, Walz JS et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol, 2021; 22, 74–85
[11] Gallais F, Velay A, Wendling MJ et al. Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion. Emerging Infectious Diseases doi: 10.3201/eid2701.203611
[12] Mahajan S, Kode V, Bhojak K et al. Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals. https://www.biorxiv.org/content/10.1101/2020.11.03.367375v1.full.pdf
[13] Weiskopf D, Schmitz KS, Raadsen MP et al. Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 26 Jun 2020: Vol. 5, Issue 48, eabd2071 DOI: 10.1126/sciimmunol.abd2071 http://immunology.sciencemag.org
[14] Le Bert N, Tan AT, Kunasegaran K et al. Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals. https://doi.org/10.1101/2020.05.26.115832
[15] Gorse GJ, Patel GB, Vitale JN et al. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. Clin. Vaccine Immunol. 2010; 17, 1875–1880
[16] Sagar M, Reifler K, Rossi M et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest. 2021;131(1):e143380. https://doi.org/10.1172/JCI143380.
[17] Glinsky GV, Impact of pre-existing SARS-CoV-2 reactive T cells in uninfected individuals on COVID-19 mortality in different countries. https://doi.org/10.1101/2020.10.03.20206151
[18] Gittelman RM, Lavezzo E, Snyder TM et al. Diagnosis and Tracking of Past SARS-CoV-2 Infection in a Large Study of Vo’, Italy Through T-Cell Receptor Sequencing. https://www.medrxiv.org/content/10.1101/2020.11.09.20228023v1
[19] Snyder TM, Gittelman RM, Klinger M et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. https://www.medrxiv.org/content/10.1101/2020.07.31.20165647v3